ISCHEMIA heart disease trial makes waves; feds want transparent health pricing
By Bruce Jancin
The largest-ever RCT of initial invasive versus conservative management of stable ischemic heart disease makes waves.
You can take the MDedge Podcasts survey by clicking here.
The goal of the proposal is to give consumers enough information to shop around for medical services.
Cancer or cancer-related treatments were covered by 41% of programs, and 34% provided assistance for genetic or rare diseases.
Further analyses from the DAPA-HF trial showed dapagliflozin cut death and heart failure events in HFrEF patients with no diabetes.
Screening can take as little as 20 seconds.